CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?

In my last coverage of CG Oncology, Inc. (NASDAQ: CGON ), I had a shift in sentiment from "Hold" to "Buy" based on key catalysts that we could look forward to in 2025. Since then, theI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investing in this space.Analys ...